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Abstract
Background: To evaluate the impact of Gallium-68 [68Ga] labeled prostate specific membrane antigen (PSMA)
positron emission tomography (PET)/X-ray computed tomography (CT) compared with conventional imaging on
staging and clinical management of men evaluated for primary prostate cancer (PCa).
Methods: Men with newly diagnosed biopsy-proven PCa who had been staged with a conventional staging protocol
including bone scintigraphy (BS) and additionally underwent [68Ga]PSMA PET/CT, were evaluated retrospectively.
Imaging findings from BS, magnetic resonance imaging (MRI) and/or CT were categorized regarding locoregional
nodal (N) and distant metastasis (M) status as negative, positive or equivocal before and after addition of the
information of PET/CT. Also, the imaging-based level of confidence (LoC) in correct assessment of N and M status was
scored. Impact of PET/CT on clinical management was evaluated by the percentage of treatment category changes
after PET/CT as determined in the multidisciplinary tumour board.
Results: Sixty-four men with intermediate and high-risk PCa were evaluated. With additional information of PET/CT, N
status was upstaged in 23%, and downstaged in 9%. M status was upstaged in 13%, and downstaged in 23%. A net
increase in LoC of 20% was noted, mainly regarding M status.
Treatment category changed from palliative to curative in 9%, and from curative to palliative in 3%. An undecided
treatment plan changed to curative in 14%, as well as to palliative in another 9%. In total, a 36% treatment category
change was noted.
High negative predictive value of PET/CT for M status was indicated by 27 patients that underwent robot-assisted
radical prostatectomy and reached postoperative biochemical disease-free status or had a likely other site of disease
recurrence.
Conclusions: PSMA PET/CT can cause considerable changes in N and M staging, as well as in management compared
to conventional staging. Findings of this study support the replacement of BS and CT by PSMA PET/CT in staging
primary PCa.
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Background
Management strategies for primary prostate cancer,
whether with curative or palliative intent, have their own
morbidities and costs. Recently estimated costs of pros-
tate cancer therapies in Australia were US$ 15 K–35 K
per patient and US$ 270.9 M in total, with an expected
increase of 42% in 2025 [1]. Imaging has a pivotal role in
staging of and selecting the appropriate management
strategy in men with primary prostate cancer. Bone scin-
tigraphy (BS) with Technetium-99 m [99mTc] labeled
bisphosphonates has been the most widely used method
for detecting bone metastases of PCa, based on visualiz-
ing the increased osteoblastic activity of bone metastases
[2]. Due to its moderate sensitivity and specificity, BS
frequently results in equivocal findings regarding the
presence of bone metastases [3–5]. Nonetheless, for pri-
mary staging of newly diagnosed PCa, BS is still recom-
mended for distant staging, combined with cross-
sectional abdominopelvic imaging for local and lymph
node staging, in all high-risk patients [2].
After its clinical introduction in 2011, PET imaging
with agents targeting the prostate-specific membrane
antigen (PSMA), a transmembrane glycoprotein that is
highly overexpressed on most PCa cells, has shown in-
creasing adoption. Its value for staging recurrent PCa
has already been well established [6].
More recently, PSMA PET/CT imaging was evaluated
as a potential tool for staging primary prostate cancer in
men prior to curative treatment [7]. Specificity rates of
84–100% were reported by earlier studies [8–11] and in a
recent systematic review [12]. However, the sensitivity of
PSMA PET/CT for the detection of lymph node metasta-
ses is moderate (33–91%), most likely due to the limita-
tions in the spatial resolution to detect small (< 3mm)
lymph node tumour deposits in primary as well as recur-
rent prostate cancer [13]. Its performance with regard to
distant metastases and impact on clinical management
compared to conventional staging is less investigated.
In our institute, a Gallium-68 [68Ga] labeled PSMA
PET/CT was added to the conventional staging proced-
ure in men with intermediate and high-risk PCa
(predominant Gleason pattern 4 or higher, and/or cT3
or higher, and/or PSA blood level ≥ 20) from June 2016
onwards. The aim of the present study is to evaluate the
impact of additional PSMA PET/CT on staging and
clinical management of men evaluated for primary PCa
compared with a conventional staging protocol.
Methods
Ethics approval
This single-center was approved by the institutional
review board of the Netherlands Cancer Institute and
the need for written informed consent for usage of
pseudonymized patient data was waived due to the
retrospective nature of the study. Approval was regis-
tered under local number IRBd19063.
Patients
For this study, all patients with newly diagnosed biopsy
proven PCa who had been staged between June 2016
and February 2018 with both [68Ga]PSMA PET/CT and
BS were identified and selected from an institutional
database, containing staging and treatment information.
According to institutional protocol diagnostic proce-
dures were performed before start of any treatment al-
though androgen deprivation therapy (ADT) at time of
imaging was allowed. Maximum time between conven-
tional imaging and PSMA PET/CT was 90 days, which
has been suggested as an acceptable interval for compar-
ing staging modalities in PCa [4].
Conventional staging
Conventional staging included a clinical T stage assess-
ment with digital rectal examination and PSA blood
level measurement as well as conventional imaging in-
cluding MRI, CT and BS. The MRI of the pelvis (multi-
parametric prostate protocol at a field strength of 1.5 T
or 3 T, without an endorectal coil) was evaluated by ex-
perienced radiologists according to PI-RADS v2. Con-
ventional size criteria thresholds were used for lymph
node evaluation [14]. BS consisted of planar images of
the entire skeleton from anterior and posterior 3–4 h
after intravenous injection of approximately 555MBq
[99mTc] labeled bisphosphonates, with additional detail
views and / or SPECT/CT imaging of a body part if
regarded necessary. All BS images were evaluated by
experienced nuclear medicine physicians.
CT images were assessed for nodal and distant metas-
tases. Generally, pelvic lymph nodes > 8 mm in max-
imum short axis diameter were regarded as positive.
Either a contrast-enhanced abdominal CT (ceCT) was
performed, or the lowdose CT (ldCT) as part of the PET
imaging was used if no ceCT was performed. The ldCT
was interpreted by two independent, experienced readers
with clinical information but blinded from PET and
other imaging results.
MRI, CT and BS findings were categorized according
to the original clinical reports for regional nodal (N) as
well as distant metastases (M) staging: negative, positive
or equivocal. For ldCT, the readers reached a consensus
on N and M stage using the same categories. A com-
posed conventional N and M stage was determined
grouping the results of the MRI, CT and / or BS. Posi-
tive status on one of the conventional imaging modal-
ities was regarded dominant over equivocal and negative
results from the other modalities. Equivocal status was
regarded dominant over negative results. The rationale
is that modalities are complemental and scan ranges
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may not overlap, therefore a result that upstages the
patient has to be disproven by additional imaging or




([68Ga]PSMA-11) was used as tracer and produced on-site
compliant to Good Manufacturing Practices regulations using
a fully automated system (Scintomics GmbH, Germany). The
tracer was administered to the patients as an intravenous
bolus injection (100MBq fixed dose). After an incubation
period of 45min, PET imaging was performed from proximal
femora to skull base on a Philips Gemini TF-II PET/CT scan-
ner (3min / bed for pelvis/abdomen and 2min / bed position
for the remainder), combined with a dose-modulated low
dose CT (40 mAs, 2mm reconstruction).
All PET/CT images were interpreted by nuclear medi-
cine physicians with experience in prostate cancer PET
imaging and reporting. Level of tracer uptake, location
and morphological appearance of lymph nodes were
considered to assess N status [7, 15, 16]. PET/CT im-
aging findings were categorized according to the original
reports for regional nodal (N) as well as distant metasta-
ses (M) staging: negative, positive or equivocal.
Treatment policies
Cases were discussed as part of standard clinical care in
the tumour board (consisting of urologists, medical on-
cologists, radiation oncologists, radiologists and nuclear
medicine physicians) with all diagnostic information
available including PSMA PET/CT. A formal TNM sta-
ging and a preferred treatment were recorded in pa-
tients’ chart. For patients with localized or regional
lymph node metastases preferred treatment options with
curative intent consisted of surgery or radiation (external
or brachytherapy) whether or not combined with andro-
gen deprivation. After therapy with curative intent,
biochemical disease status was assessed with serum PSA
measurements during follow up. Patients with high
suspicion for distant metastases were considered for
palliative treatment (ADT +/− chemotherapy).
For purpose of the study, cases were discussed again
in a smaller expert group (MD, PvL, HvdP) without
information from PSMA PET/CT and a fictional TNM
staging and preferred treatment was recorded in the
study database.
Impact of PSMA PET/CT on staging
Per patient, the tumour N and M stage based on the
composed conventional staging was compared to the
tumour stage based on the additional information of the
PSMA PET/CT. Differences in observed staging frequen-
cies were tested for independence using a Chi-square
test (IBM SPSS Statistics v25; Armonk, NY, USA). For
both N and M staging, upstaging was defined as a
change from negative to equivocal or positive, or from
equivocal to positive. Downstaging was defined as a
change from positive to equivocal or negative, or from
equivocal to negative.
Furthermore, the level of confidence (LoC) in the
correct assessment of the tumour stage based on the
imaging findings was defined. This was done according
to above mentioned N and M staging three-category
systematics. For both N and M staging, increase in LoC
was defined as a change from equivocal to positive or
negative. Decrease in LoC was defined as a change from
positive or negative to equivocal.
Impact of PSMA PET/CT on clinical management
Based on the recorded tumour stage with and without
information from PSMA PET/CT, patients were divided
into one of three categories of intended treatment: ‘cura-
tive treatment’, ‘palliative treatment’, or ‘undecided’. ‘Un-
decided’ was assigned in case of equivocal M stage based
on the conventional staging. The impact of PSMA PET/
CT on clinical management was defined as a change of
treatment category after additional PSMA PET/CT.
Results
Patients
Sixty-four men with a BS and a [68Ga]PSMA PET/CT
meeting the inclusion criteria were identified from the
database (Fig. 1). Eight (13%) had intermediate-risk PCa
and 56 (87%) had high-risk PCa. Four patients used the
antiandrogenic oral drug bicalutamide and one patient
used a gonadotrophin-releasing hormone analogue at
time of PSMA PET/CT. Baseline patient characteristics
are presented in Table 1. Performed imaging as part of
the conventional staging protocol and median time
between conventional imaging and PSMA PET/CT are
presented in Table 2.
Impact on staging
Significant differences in N and M staging frequencies
were found for CT and MRI, and for CT respectively
compared to PSMA PET (Table 3). The linear weighted
Kappa for the ldCT readers’ agreement was 0.5 for N
stage and 0.58 for M stage. Based on conventional
staging, 41 patients (64%) were staged as negative, ten
(16%) as positive, and thirteen (20%) as equivocal for
nodal metastases. With additional information of the
PSMA PET/CT, 15 (23%) were upstaged, six (9%) were
downstaged, and 43 (67%) remained unchanged.
Based on conventional staging, 37 patients (58%) were
staged as negative, 12 (19%) as positive, and 15 (23%) as
equivocal for distant metastases. With additional infor-
mation of the PSMA PET/CT eight (13%) were
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upstaged, 15 (23%) were downstaged, and 41 (64%)
remained unchanged. A net increase in LoC of 20% was
noted, mainly regarding M status. Further frequencies
and changes in staging and LoC are presented in
Tables 3 and 4.
Twenty-seven patients underwent RARP. Eighteen of
these reached biochemical disease-free status (defined as
serum PSA < 0.01 after RARP without hormonal treat-
ment), confirming absence of distant metastases as
established with PET/CT staging. Notably, four of these
Fig. 1 Flowchart of staging and treatment intent changes after PSMA PET/CT compared to conventional staging. * predominant Gleason pattern
4 or higher, and/or cT3 or higher, and/or PSA blood level≥ 20
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patients were staged positive and two equivocal with
conventional staging.
Nine patients did not reach postoperative biochemical
disease-free status. Eight of these were categorized as M-
negative, one as equivocal on PSMA PET. The most
likely source of disease in these patients were remaining
nodal metastases, because the majority of patients (8/9)
had histologically proven nodal positive status after pel-
vic lymph node dissection (PLND) and follow-up PSMA
PET/CT in all patients within a year after surgery
(median 7 months, range 3–11) showed nodal metastases
as the only site of recurrence in five patients, no
localization in three patients, and multiple localizations
including lymph nodes in one patient.
Impact on clinical management
With additional information of the PSMA PET/CT, in
15 patients (23%) the treatment category changed from
palliative (n = 6) or undecided (n = 9) to curative. In
eight patients (13%) the treatment category changed
from curative (n = 2) or undecided (n = 6) to palliative.
In 41 patients (64%) the treatment category based on
conventional staging did not change.
The impact of PSMA PET/CT on treatment intent is
presented in Table 5 and Fig. 1, and illustrated in Fig. 2.
Discussion
In this study, the clinical impact of additional diagnostic
information from PSMA PET/CT was compared with
conventional staging in patients with intermediate and
high-risk prostate cancer. A considerable impact on both
staging and clinical management was found. Compared to
conventional primary staging of PCa, PSMA PET/CT
changed N stage in 33% and M stage in 36%, resulted in a
net increase in the LoC of 9% for N status and of 20% for
M status, and led to a treatment category change in 36%.
A growing number of studies compared PSMA PET/
CT with conventional primary staging for primary PCa.
Earlier studies found superior detection rates of PSMA
PET/CT for bone metastases compared to BS in primary
PCa patients [3, 4, 17]. Furthermore, PSMA PET/CT
induced management changes were reported by Roach
Table 1 Baseline characteristics
Total number of patients 64
Age in years, median (range) 69 (49–83)














≥ 9 15 (23%)
Risk stratification
Intermediate risk 8 (13%)
High-risk 56 (87%)
ADT use at time of PSMA PET/CT
Yes 5 (8%)
No 59 (92%)
aPredominant Gleason score 3
bPredominant Gleason score 4
Table 2 Imaging characteristics
Total number of patients 64
Imaging performed




MRI prostatea 59 (92%)
CT abdomen
low dose 54 (84%)
contrast enhancedb 10 (16%)
Conventional imaging and PET/CT interval, median (range) 49 days (−12 to 87)
ain 5 patients no MRI available due to evident distant metastases on PSMA PET/CT [3], due to severe claustrophobia [1] and performed elsewhere [1]
bdiagnostic abdominal CT with intravenous iodine-containing contrast in portal venous phase
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Table 3 Comparison of conventional and PSMA PET/CT staging. n = 64 patients
A. Staging frequencies
N stage CT MRI Conventionala PSMA PET/CT
negative 44 (69%) 43 (67%) 41 (64%) 38 (59%)
equivocal 9 (14%) 8 (13%) 10 (16%) 4 (6%)
positive 11 (17%) 8 (13%) 13 (20%) 22 (34%)
not available – 5 (8%)b
M stage Bone scintigraphy CT MRI Conventionala PSMA PET/CT
negative 44 (69%) 54 (84%) 3 (5%) 37 (58%) 48 (75%)
equivocala 9 (14%) 6 (9%) 5 (8%) 15 (23%) 3 (5%)
• M1b: 9 (14%) • M1a: 2 (3%) • M1b: 9 (14%) • M1b: 3 (5%)
• M1b: 4 (6%)
positive 11 (17%) 4 (6%) 0 12 (19%) 13 (20%)
• M1a: 2 (3%)
• M1b: 9 (14%)
• M1c: 2 (3%)
not reported 51 (80%)
not availableb 5 (8%)
B. Contingency tables for observed staging frequencies
N stage
negative equivocal positive Totals
Conventionala 41 10 13 64
PSMA PET/CT 38 4 22 64
Totals 79 14 35 128
X2 (2, N = 64) = 5.0; p = .0821
negative equivocal positive Totals
CT 44 9 11 64
PSMA PET/CT 38 4 22 64
Totals 82 13 33 128
X2 (2, N = 64) = 6.0; p = .049076*
negative equivocal positive Totals
MRI 43 8 8 59
PSMA PET/CT 38 4 22 64
Totals 81 12 30 123
X2 (2, N = 64) = 8.0; p = .018451*
M stage
negative equivocal positive Totals
Conventionala 37 15 12 64
PSMA PET/CT 48 3 13 64
Totals 85 18 25 128
X2 (2, N = 64) = 9.5; p = .008811*
negative equivocal positive Totals
Bone scintigraphy 44 9 11 64
PSMA PET/CT 48 3 13 64
Totals 92 12 24 128
X2 (2, N = 64) = 3.3; p = .188193
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et al. in 21% of a larger cohort of primary PCa patients
[18].
The recently published prospective multicentre
proPSMA trial confirms the superior accuracy of PSMA
PET/CT to conventional imaging (CT and bone scintig-
raphy) in assessing pelvic nodal and distant metastatic
disease (92% vs 65%) in high-risk primary PCa [19]. Fur-
thermore, equivocal findings were less (7% vs 23%) and
PSMA PET/CT conferred more management changes
(28% vs 15%). Also, when used as second-line imaging
which is comparable to our study setting, PSMA PET/
CT resulted in significant upstaging of nodal status com-
pared to conventional imaging (23,3% vs. 8,8% positive)
and management changed occurred in 27%.
The findings of our study are in line with abovemen-
tioned studies. In 33% of patients N stage was changed
with information from PSMA PET/CT, mostly resulting
in upstaging (23%). Although correctness of these find-
ings could not be formally assessed in our study, the
high reported specificity of PSMA PET/CT for nodal
metastases in primary staging of PCa suggests that
upstaging would be correct in most cases, warranting
considerable changes in patient management, such as
increasing the extent of the PLND or the radiotherapy
field [8–11, 20, 21].
PSMA PET/CT-induced treatment category changes
in our study ranged from a conservative 13% (curative to
palliative, or vice versa) to an optimistic 36% (any treat-
ment category change). This is in line with abovemen-
tioned studies as well. Prostate cancer management is
likely to be more and more patient-tailored and adjusted
to staging information of imaging, such as tumour delin-
eation in radiotherapy planning which may be signfi-
cantly influenced by PSMA PET/CT [21]. Findings that
may not result in a considerable management change
now, may do so in the future. The LoC in determining
the correct N stage was considerably higher with PSMA
PET/CT compared to conventional staging, though
equivocal results remained in up to 6%. This is compar-
able with abovementioned studies as well. Further devel-
opment of structured reporting criteria for negative and
positive nodes may help to reduce the number of
equivocal results and increase the LoC [15].
The major limitation of our study is the retrospective
nature. Impact of PSMA PET/CT may be overestimated
because patients may have been more likely to receive a
PSMA PET/CT because of inconclusive findings on con-
ventional imaging. Patients with overt metastases on BS
probably are underrepresented because PSMA PET/CT
may have been omitted due to lack of clinical conse-
quences, and this may have overestimated staging and
management impact of PSMA PET/CT as well. How-
ever, this reflects clinical practice as BS is cheaper and
more readily available and may serve as an adequate first
line M staging tool in patients with highly elevated PSA
levels. Furthermore, a true gold standard (histopath-
ology) lacks in most cases, especially for distant metasta-
ses. The final diagnosis is substantially influenced by the
findings of the PSMA PET/CT itself, leading to incorp-
oration bias and overestimating the accuracy of PSMA
PET/CT. The management changes described here how-
ever represent clinical practice. Although predefined
rules were followed, the setting of the smaller unblinded
expert group may have influenced the results of the
fictional restaging and subsequent preferred treatment.
Finally, the proportion of contrast-enhanced CTs in this
study was low. Although literature showed poor sensitiv-
ity for CT in determining N stage and no established
role in determining M stage in primary PCa, the
comparison of PSMA PET/CT with conventional staging
in our study may have been limited [22].
Use of ADT at time of PSMA PET imaging is allowed
according to EANM procedure guideline on 68Ga-
PSMA PET/CT imaging [23], however tracer uptake and
Table 3 Comparison of conventional and PSMA PET/CT staging. n = 64 patients (Continued)
negative equivocal positive Totals
CT 54 6 4 64
PSMA PET/CT 48 3 13 64
Totals 102 9 17 128
X2 (2, N = 64) = 6.1; p = .046943*
acomposed conventional stage grouping results of bone scintigraphy, CT and MRI
bin 5 patients no MRI available due to evident distant metastases on PSMA PET/CT [3], due to severe claustrophobia [1] and performed elsewhere [1]
*denotes significance at alpha. 05 (Chi-square test of independence)
Table 4 Impact of PSMA PET/CT staging and level of
confidence on a per-patient level. n = 64 patients
N stage N Status LoCa
up 15 (23%) 9 (14%)
down 6 (9%) 3 (5%)
no change 43 (67%) 52 (81%)
M stage M Status LoCa
up 8 (13%) 15 (23%)
down 15 (23%) 2 (3%)
no change 41 (64%) 47 (73%)
aLoC: imaging-based level of confidence in correct assessment of N and
M status
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therefore PET staging results may be influenced by ADT
[24]. As only five of 64 patients were undergoing hormo-
nal therapy at time of PSMA PET, we do not think this
has impacted our results.
The purpose of this study was not to assess the com-
parative accuracy of the conventional staging and the
staging with PSMA PET/CT. Since histopathological
confirmation of N status in the non-surgical treatment
group lacked and confirmation of M status clinically was
not feasible or did not have consequences, a true gold
standard was not available. However, a high negative
predictive value of PSMA PET/CT for M status is
Table 5 Treatment plan based on conventional vs PSMA PET/CT staging procedure. n = 64 patients
Conventional staging PSMA PET/CT staging Impact of PSMA PET/CT
Curative 40 (63%) 53 (83%) Remains curative 38 (59%)
Undecided 15 (23%) 0 Palliative to curative 6 (9%)
Palliative 9 (14%) 11 (17%) Undecided to curative 9 (14%)
Undecided to palliative 6 (9%)
Curative to palliative 2 (3%)
Remains palliative 3 (5%)
Fig. 2 Example of staging change of PSMA PET/CT compared with conventional imaging. A man presented with a clinical T2c Gleason 7b
(predominant Gleason score 4) PCa with an iPSA of 16. Planar BS (a) showed a faint spot in the left proximal femur (red arrow) which was
confirmed on SPECT/CT (b) as a sclerotic lesion with osteoblastic activity (red arrow). The lesion was interpreted as suspicious for bone metastasis.
Other areas with increased osteoblastic activity (green arrows) were interpreted as degenerative. A [68Ga]PSMA PET/CT (c) 36 days later shows a
PSMA positive bilateral PCa (blue arrow), but no PSMA expression in the sclerotic lesion in the left proximal femur (d, red arrow). Based on PSMA
PET/CT the lesion in the left proximal femur was regarded as not suspicious for bone metastasis; M stage changed from positive to negative and
treatment intent changed from palliative to curative
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indicated by the 27 patients treated with RARP who
reached biochemical disease-free status or were likely to
have alternative sites of residual disease. Notably four of
these patients were staged positive and two of them
equivocal with conventional staging method. Thus, in
addition to reported higher sensitivity of PSMA PET/CT
for bone metastases compared to BS in primary staging
of PCa [4], our data indicate a superior specificity of
PSMA PET/CT compared to conventional staging.
Conclusions
Compared to conventional primary staging of PCa,
PSMA PET/CT changes N stage in 33% and M stage in
36%, leading to treatment category change in 36%. BS
was false-positive for distant metastases in 15–22% of
cases. Findings of this study support the replacement of
BS and CT by PSMA PET/CT in primary staging of
PCa, but prospective analyses are needed to confirm a
possible beneficial effect on survival outcome.
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